Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MBVXQ: Bankruptcy PLAN effective. All shares cancelled.
https://otce.finra.org/otce/dailyList?viewType=Deletions
is this sh...t still allowed? and trading?????.
So what exactly does this mean? Can they bounce back?
MBVX changed to MBVXQ, bankruptcy:
https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes
Bankruptcy will do that
Xena: Do you, or anyone else here, happen to know if Honig's longtime associate Joseph Salvani is involved in MBVX?
From last 10k, almost 1 million in cash and almost 9 million in assets. Trading way below cash value. With this merger news, this could explode to all time highs. Just needs more eyes and more volume
This moves past .50 on Monday. History of big swings . With actual legit news this is priced to move. Like what I’m seeing
Should be interesting here
8k out, possible merger with Oncotelic Inc!
https://www.otcmarkets.com/filing/html?id=13139632&guid=qqr8U6f3Z3vFrth
Mabvax and Phillip Frost:
https://www.sec.gov/Archives/edgar/data/898860/000165495418000871/0001654954-18-000871-index.htm
Frost named in SEC lawsuit:
New lawsuit filed involving P&D by significant institutions.
I never chase runs and stayed out. It just makes me angry to see what they did.
It was a nanocap pump and dump. Was it criminal? Kinda. Will anything be done? No. Hope you didn't buy into that 200% increase the other day. That was for insiders to get out before the delisting. It had nothing to do with bigger and better things.
Light up the investor relations lines. What is happening here is criminal.
Being delisted I guess...
This has been the trend with these runners. Run up then pull back for a few days/weeks. Almost bought at $1.50 yesterday, glad I didn’t.
Very cheap here after pullback. A (what was) a 6 million market cap company got 11 million upfront AND milestone payments for something they were not even in trails for. They didn't sell anything they were working on. Large potential at a very cheap price.
Wow, what a sell off. Everybody shorting?!
Awesome "analysis".......
* * $MBVX Video Chart 07-09-18 * *
Link to Video - click here to watch the technical chart video
The news was great the float was perfect for a huge run to $3.00 plus today and this AM it looked like it would. However the trading on the way down was brutal. It happens every time any stock with a low float goes down and people get out with stop losses and losses below. Congrats to those who did make %$$ today it was not easy at all this afternoon but this AM was fun.
I mean from the highs, why is it not sustaining the gains? Ofcourse my opinion
Why the selloff? What are we missing here?
Agreed! The payment they are receiving is 25% more than what the company is currently valued!
MBVX has such a tiny float like all of the biggest runners we see on the big boards that is why we get halted so much. I am betting on over $3.00 to $5.00 ahead on the charts.
Happy to be here!!! Any predictions on where we’ll close?!
Been too busy working my summertime low-float gainers.....
Do not get why the board has been so quiet today but we have a low float gem here on HUGE news.
MBVX
Put this one on your radar just for the bounce.
Wow they acted fast on that, shows amazing initiative to get right with the SEC
MBVX According to PR, partnership/investor news due out any day now. S1 cancellation also hints at this happening. Good Luck
consolidating nicely... with the low float this should pop - on any news
Some short cover caused a small pop in the price JMHO
* * $MBVX Video Chart 10-11-17 * *
Link to Video - click here to watch the technical chart video
Hot hot hot
Stetson John has filed a new 13G, reporting 5.64% ownership in $MBVX - https://fintel.io/soh/us/mbvx/stetson-john and https://fintel.io/i/stetson-john
Followers
|
57
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1194
|
Created
|
04/12/01
|
Type
|
Free
|
Moderators |
| MabVax Therapeutics Holdings is a clinical-stage biopharmaceutical company focused on discovering and developing innovative vaccine and monoclonal antibody-based therapeutics for the diagnosis and treatment of cancer. We generate our pipeline of antibody-based product candidates from patients who have been vaccinated with propriety vaccines licensed from Memorial Sloan-Kettering Cancer Center, or MSKCC. Our approach of surveying the protective immune response from many patients to identify the ideal monoclonal antibody candidate against a specific target on the surface of a cancer cell is a novel next-generation human antibody technology platform. Our approach to antibody discovery is to seek to identify the antibody candidates with superior performance characteristics while minimizing many of the toxicity and off target binding drawbacks of other discovery technologies. Our lead antibody candidates have been recovered from patients who had substantially better treatment outcomes than almost all other patients in clinical trials we conducted or that were conducted by our partners. Our therapeutic vaccines were developed at MSKCC and are exclusively licensed to us pursuant to agreements with MSKCC in 2008. These vaccines are administered in the adjuvant (period following conventional treatment consisting of watchful waiting) setting and have shown in clinical studies to elicit a protective antibody response. The antibodies are intended to seek out circulating tumor cells and micrometastases (small clusters of cancer cells) to kill them before they can cause cancer recurrence. Our lead cancer vaccines targeting recurrent sarcoma (soft tissue cancer) and ovarian cancer are currently in proof of concept Phase II multi-center clinical trials. Both trials have received substantial federal grant monies to support their development. A vaccine to address the orphan disease neuroblastoma (cancer starting in the adrenal gland of children which may spread to nervous tissue and bone marrow) has completed an initial Phase I trial at MSKCC and is expected be ready for a Phase II trial by early 2015. MSKCC and the Company have completed additional Phase I vaccine clinical trials in melanoma, ovarian cancer, and small cell lung cancer over the last three years.MBVX Intraday Stock Chart
My Stocks Activity For MBVX
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |